NEW YORK, May 23, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it is...
NY false 0001802768 0001802768 2022-05-17 2022-05-17 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ...
New capital deployment target of $10-12 billion over the next five yearsOutlook for 2020-2025 Adjusted Cash...
FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction...
NY false 0001802768 0001802768 2022-05-10 2022-05-10 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ...
0001802768December 312022Q1FALSE44Subsequent Events]00018027682022-01-012022-03-310001802768us-gaap:CommonClassAMember2022-05-02xbrli:shares0001802...
0001802768false00018027682022-05-052022-05-05UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549FORM 8-K CURRENT REPORTPursuant...
Net cash provided by operating activities (GAAP) of $460 million; Adjusted Cash Receipts(1) (non-GAAP) of $605...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy...
TABLE OF CONTENTS UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549SCHEDULE 14AProxy Statement Pursuant to Section 14(a)of...
NEW YORK, April 18, 2022 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has...
FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.